Clinical trials: Female Breast Neoplasms
Breast Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087178
- Testing
- cyclophosphamide, adriamycin, epirubicin
- Where
- 606 sites in United States, Canada and 1 more
- Volunteers
- 2,722 people
- Sponsor
- NSABP Foundation Inc
Breast Neoplasm Female, Quality of Life
Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib
Combining a fitness tracker technology with real-time patient-reported outcome monitoring associated with interventions through a health care app is a novel strategy to evaluate metastatic breast cancer patients using Palbociclib…
- Trial name
- WEFITTER (NCT05277935)
- Testing
- Use of the WeCancer app combined with the smartwatch.
- Where
- 4 sites in Brazil
- Volunteers
- 68 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Breast Cancer Female
Moving On Study - Pilot Test
The purpose of this study is to conduct a pilot test of "Moving On After Breast Cancer (MOVE-ABC)" - a physical therapy based educational intervention designed to reduce and manage breast cancer-related physical and functional…
- Trial name
- MOST-PT (NCT04681989)
- Testing
- Moving On After Breast Cancer
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Breast Cancer
5 Years Follow-up With Adjuvant Therapy for Women With Breast Invasive Carcinoma
Non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its efficacy. The objective of this study is to know the women experience (persistence, treatment changes, quality of life) and its determinants…
- Trial name
- HACAMI (NCT02791750)
- Testing
- questionnary of quality of life
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut de Cancérologie de Lorraine
Breast Cancer
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, docetaxel,, paclitaxel, and ixabepilone work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- NCT00637897
- Testing
- docetaxel, ixabepilone, paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer Female
Mind Programme for Women With Breast Cancer
The Mind programme for cancer patients was developed by this project PI through the integration of ACT, mindfulness and CFT components specifically adapted to the needs of a cancer population.
- Trial name
- MIND (NCT05642897)
- Testing
- Mind, Support Group
- Where
- Portugal
- Volunteers
- 150 people
- Sponsor
- University of Coimbra
Breast Cancer
Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy
The main purpose of the investigation is to determine if curcumin reduces NF-kB DNA binding and ultimately its downstream mediator IL-6 in patients receiving XRT for their breast cancer after having completed chemotherapy.
- Trial name
- NCT01740323
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Andrew H Miller
Breast Cancer Female, Breast Cancer Prevent
First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer
This study is a first in human, two-stage single arm non-comparative study of safety and performance. The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering…
- Conditions
- Breast Cancer Female, Breast Cancer Prevent, Breast Reconstruction
- Trial name
- TIDE (NCT05460780)
- Testing
- MATTISSE TEC
- Where
- 3 sites in France, Georgia
- Volunteers
- 50 people
- Sponsor
- Quanta Medical
Breast Cancer Female
Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction
The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to anatomical landmarks for partial breast reconstruction.
- Trial name
- (LaPBrecon) (NCT07006662)
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University Hospitals of North Midlands NHS Trust
Breast Cancer
BN83495 Phase I in Post-menopausal Women
The purpose of this study is to determine the optimal biological dose (OBD) of Irosustat (BN83495) in postmenopausal women with oestrogen receptor (ER) positive locally advanced or metastatic breast cancer with disease…
- Trial name
- NCT01840488
- Testing
- Irosustat (BN83495)
- Where
- 5 sites in Belgium, France and 1 more
- Volunteers
- 50 people
- Sponsor
- Ipsen
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00929591
- Testing
- cyclophosphamide, doxorubicin hydrochloride, endocrine therapy
- Volunteers
- 1,558 people
- Sponsor
- SWOG Cancer Research Network
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Ovarian Cancer
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- NCT06065059
- Testing
- TNG348, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Tango Therapeutics, Inc.
Breast Cancer, Lung Cancer
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Background: Paclitaxel is a chemotherapy drug that is commonly used to treat different types of cancers. However, cancer tumors can become resistant to paclitaxel, and as a result they will fail to accumulate sufficient…
- Conditions
- Breast Cancer, Lung Cancer, Renal Cancer, Adrenal Cancer
- Trial name
- NCT01086696
- Testing
- FPAC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
This study will assess the efficacy and safety of intravenous (IV) trastuzumab (Herceptin) and IV docetaxel (Taxotere), with or without oral capecitabine (Xeloda), in women with previously untreated HER2-positive advanced and/or…
- Trial name
- NCT02748213
- Testing
- Xeloda, Taxotere, Herceptin
- Where
- 51 sites in Australia, Brazil and 13 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Invasive Breast Cancer
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.
- Trial name
- NCT03564782
- Testing
- PVSRIPO
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Istari Oncology, Inc.
Breast Cancer Female, HER2-positive Breast Cancer
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
This study is a single-arm, open-label, phase II study, comparing the efficacy and safety of pyrotinib plus trastuzumab and aromatase inhibitors, in the treatment of HR (hormone receptor)+/HER2 (human epidermal growth factor…
- Conditions
- Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
- Trial name
- NCT04088110
- Testing
- Pyrotinib, Trastuzumab, Aromatase Inhibitors
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Fuzhou General Hospital
Invasive Breast Cancer
Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM"
This is a prospective examination of tumor material of breast cancer patients randomized into the FinHer-trial (= (= Comparison of vinorelbine and docetaxel and trastuzumab as adjuvant treatments of breast cancer patients wirh a…
- Trial name
- NCT02244580
- Testing
- MammaTyper™
- Volunteers
- 1,010 people
- Sponsor
- BioNTech Diagnostics GmbH
Ovarian Neoplasm, Cancer Genetics
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Background: Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it.
- Conditions
- Ovarian Neoplasm, Cancer Genetics, Breast Cancer
- Trial name
- NCT01374685
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.